Avidity Partners Management LP Uni Qure N.V. Transaction History

Avidity Partners Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$8.34 - $17.27 $1.08 Million - $2.23 Million	-129,200 Reduced 38.43%	207,000 $2.89 Million
Q1 2025 May 15, 2025	BUY	$10.6 - $18.08 $1.21 Million - $2.06 Million	114,200 Added 51.44%	336,200 $3.56 Million
Q4 2024 Feb 14, 2025	SELL	$4.54 - $17.73 $2.05 Million - $8.01 Million	-451,618 Reduced 67.04%	222,000 $3.92 Million
Q3 2024 Nov 14, 2024	BUY	$3.78 - $10.12 $2.55 Million - $6.82 Million	673,618 New	673,618 $3.32 Million
Q2 2020 Aug 14, 2020	SELL	$45.06 - $67.74 $10.7 Million - $16.1 Million	-237,000 Closed	0 $0

Q1 2020 Jun 17, 2020	BUY	$40.01 - $73.97 $9.48 Million - $17.5 Million	237,000 New	237,000 $11.2 Million
Q1 2020 May 15, 2020	SELL	$40.01 - $73.97 $2.2 Million - $4.07 Million	-55,000 Closed	0 $0
Q4 2019 Jun 17, 2020	BUY	$37.13 - $74.62 $2.04 Million - $4.1 Million	55,000 New	55,000 $3.94 Million

267

51.7M

3.92M

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $1.4B
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.